Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

BACKGROUND: Replication-competent virus vector vaccines might have advantages compared with non-replicating vector vaccines. We tested the safety and immunogenicity of an oral adenovirus serotype 4 vector vaccine candidate (Ad4-H5-Vtn) expressing the haemagglutinin from an avian influenza A H5N1 vir...

Descripción completa

Detalles Bibliográficos
Autores principales: Gurwith, Marc, Lock, Michael, Taylor, Eve M, Ishioka, Glenn, Alexander, Jeff, Mayall, Tim, Ervin, John E, Greenberg, Richard N, Strout, Cynthia, Treanor, John J, Webby, Richard, Wright, Peter F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science ;, The Lancet Pub. Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3576519/
https://www.ncbi.nlm.nih.gov/pubmed/23369412
http://dx.doi.org/10.1016/S1473-3099(12)70345-6

Ejemplares similares

Ejemplares similares